These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36240985)

  • 1. Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities.
    Nainwal N
    Pulm Pharmacol Ther; 2022 Dec; 77():102170. PubMed ID: 36240985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.
    Saha T; Quiñones-Mateu ME; Das SC
    Int J Pharm; 2022 Aug; 624():122042. PubMed ID: 35868481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
    Tu YF; Chien CS; Yarmishyn AA; Lin YY; Luo YH; Lin YT; Lai WY; Yang DM; Chou SJ; Yang YP; Wang ML; Chiou SH
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of repurposed antiviral drugs: Lessons from COVID-19.
    Martinez MA
    Drug Discov Today; 2022 Jul; 27(7):1954-1960. PubMed ID: 35192924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?
    Mehta A; Michler T; Merkel OM
    Adv Healthc Mater; 2021 Apr; 10(7):e2001650. PubMed ID: 33506607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.
    Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M
    J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
    Saul S; Einav S
    ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pandemic of Coronavirus Disease 2019 (COVID-19).
    Rashid NN
    Curr Mol Med; 2022; 22(9):761-765. PubMed ID: 34789125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational antiviral drugs for the treatment of COVID-19 patients.
    Beheshtirouy S; Khani E; Khiali S; Entezari-Maleki T
    Arch Virol; 2022 Mar; 167(3):751-805. PubMed ID: 35138438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives for repurposing drugs for the coronavirus disease 2019.
    Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.